Table K2Comparing performance of PCA3 levels and percent free PSA (%fPSA) measurements in matched studies via AUC analysis to correctly diagnose prostate cancer, as defined by a positive biopsy

AuthoraYearNumberInitial BxPCA3 AUC%fPSA AUCDifferencebP-valuec
Auprich220111270%0.70300.7300-0.0270
Ferro42012151100%0.7100NR-0.036
Ploussard520103010%0.68800.57100.1170-
Aubin1201010720%0.69300.51900.17400.04
Bollito22012124659%0.67800.62000.0580
All2897

Bx = biopsy, AUC = area under the curve, ‘-‘ = no value reported, NR = not reported

a

Shaded rows indicate studies focusing on the ‘grey zone’ of tPSA.

b

AUC (PCA3) – AUC (tPSA), all comparisons were between all subjects, regardless of repeat / initial biopsy status

c

Reported p-value for the comparison of the two AUCs computed among the same set of men

Shaded rows indicate studies focusing on the ‘grey zone’ of tPSA.

AUC (PCA3) – AUC (tPSA), all comparisons were between all subjects, regardless of repeat / initial biopsy status

Reported p-value for the comparison of the two AUCs computed among the same set of men

From: Appendix K, Summary of the Remaining Combined Analyses for KQ 1 and KQ 2

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer
PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 98.
Bradley LA, Palomaki G, Gutman S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.